CZ301367B6
(cs)
*
|
1998-11-10 |
2010-02-03 |
Janssen Pharmaceutica N. V. |
Derivát pyrimidinu, zpusob a meziprodukty pro jeho prípravu a lécivo pro lécení HIV na jeho bázi
|
GB9914258D0
(en)
*
|
1999-06-18 |
1999-08-18 |
Celltech Therapeutics Ltd |
Chemical compounds
|
AU775360B2
(en)
|
1999-09-24 |
2004-07-29 |
Janssen Pharmaceutica N.V. |
Antiviral compositions
|
DE19945982A1
(de)
|
1999-09-24 |
2001-03-29 |
Knoll Ag |
Geschwindigkeitsbestimmte Partikel
|
WO2001025220A1
(fr)
|
1999-10-07 |
2001-04-12 |
Amgen Inc. |
Inhibiteurs de triazine kinase
|
HUP0301117A3
(en)
|
2000-02-17 |
2004-01-28 |
Amgen Inc Thousand Oaks |
Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
|
EP1282607B1
(fr)
|
2000-05-08 |
2015-11-11 |
Janssen Pharmaceutica NV |
Promedicaments a base de pyrimidines inhibant la replication du vih
|
JP5230050B2
(ja)
|
2000-05-08 |
2013-07-10 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
Hiv複製阻害剤
|
CN100339846C
(zh)
*
|
2000-11-01 |
2007-09-26 |
斯雷普内姆斯·Com公司 |
对域名数据的状态变化进行实时监测并即时注册的系统及方法
|
US6958211B2
(en)
|
2001-08-08 |
2005-10-25 |
Tibotech Bvba |
Methods of assessing HIV integrase inhibitor therapy
|
US7638522B2
(en)
|
2001-08-13 |
2009-12-29 |
Janssen Pharmaceutica N.V. |
Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
|
JO3429B1
(ar)
|
2001-08-13 |
2019-10-20 |
Janssen Pharmaceutica Nv |
مشتقات برميدينات مثبطة فيروس الايدز
|
US8101629B2
(en)
|
2001-08-13 |
2012-01-24 |
Janssen Pharmaceutica N.V. |
Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
|
US6939874B2
(en)
|
2001-08-22 |
2005-09-06 |
Amgen Inc. |
Substituted pyrimidinyl derivatives and methods of use
|
US7115617B2
(en)
|
2001-08-22 |
2006-10-03 |
Amgen Inc. |
Amino-substituted pyrimidinyl derivatives and methods of use
|
JP4460292B2
(ja)
|
2001-10-17 |
2010-05-12 |
ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト |
ピリミジン誘導体、これらの化合物を含む医薬組成物、その使用及びその調製方法
|
EP1453516A2
(fr)
|
2001-10-17 |
2004-09-08 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Nouvelles pyrimidines substituees, procede permettant de les produire et leur utilisation comme medicament
|
HUP0402330A3
(en)
|
2001-11-01 |
2010-03-29 |
Janssen Pharmaceutica Nv |
Amide derivatives as glycogen synthase kinase 3-beta inhibitors, process for producing them, pharmaceutical compositions containing them and use thereof
|
CA2463822A1
(fr)
|
2001-11-01 |
2003-05-08 |
Janssen Pharmaceutica N.V. |
Heteroaryl amines utiles comme inhibiteurs de glycogene synthase kinase 3beta (inhibiteurs de gsk3)
|
SE0104140D0
(sv)
|
2001-12-07 |
2001-12-07 |
Astrazeneca Ab |
Novel Compounds
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
WO2003075929A1
(fr)
|
2002-03-13 |
2003-09-18 |
Janssen Pharmaceutica N.V. |
Inhibiteurs de l'histone déacétylase
|
ATE396971T1
(de)
|
2002-03-13 |
2008-06-15 |
Janssen Pharmaceutica Nv |
Sulfonylaminoderivate als neue inhibitoren von histondeacetylase
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
CN1290893C
(zh)
*
|
2002-05-03 |
2006-12-20 |
詹森药业有限公司 |
聚合物微乳状液
|
AR039540A1
(es)
*
|
2002-05-13 |
2005-02-23 |
Tibotec Pharm Ltd |
Compuestos microbicidas con contenido de pirimidina o triazina
|
TW200409629A
(en)
|
2002-06-27 |
2004-06-16 |
Bristol Myers Squibb Co |
2,4-disubstituted-pyridine N-oxides useful as HIV reverse transcriptase inhibitors
|
CN103169708B
(zh)
|
2002-07-29 |
2018-02-02 |
里格尔药品股份有限公司 |
用2,4‑嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法
|
WO2004016581A1
(fr)
*
|
2002-08-09 |
2004-02-26 |
Janssen Pharmaceutica N.V. |
Procedes de preparation de 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
|
EP1551372B8
(fr)
|
2002-09-20 |
2018-08-01 |
Alpharma Pharmaceuticals LLC |
Sous-unite de sequestration et compositions et procedes associes
|
CA2502970A1
(fr)
*
|
2002-11-28 |
2004-06-10 |
Schering Aktiengesellschaft |
Pyrimidines inhibitrices de chk-, pdk- et de akt, production et utilisation de ces composes comme agents pharmaceutiques
|
GEP20084540B
(en)
|
2003-01-14 |
2008-11-25 |
Arena Pharm Inc |
1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
|
AP2005003365A0
(en)
*
|
2003-02-07 |
2005-09-30 |
Janssen Pharmaceutica Nv |
Hiv inhibiting 1, 2, 4-triazines.
|
KR20110132482A
(ko)
|
2003-02-07 |
2011-12-07 |
얀센 파마슈티카 엔.브이. |
Hiv 감염 예방용 피리미딘 유도체
|
CL2004000303A1
(es)
*
|
2003-02-20 |
2005-04-08 |
Tibotec Pharm Ltd |
Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
|
DE602004021472D1
(en)
*
|
2003-02-20 |
2009-07-23 |
Smithkline Beecham Corp |
Pyrimiidinverbindungen
|
CN1822843B
(zh)
*
|
2003-07-17 |
2010-04-28 |
泰博特克药品有限公司 |
制备含有抗病毒药物颗粒的方法
|
RS53109B
(en)
|
2003-07-30 |
2014-06-30 |
Rigel Pharmaceuticals Inc. |
2,4 PIRIMIDINDIAMINE COMPOUNDS FOR USE IN TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES
|
DE602004031641D1
(de)
*
|
2003-09-25 |
2011-04-14 |
Janssen Pharmaceutica Nv |
Die replikation von hiv hemmende purinderivate
|
JP5213228B2
(ja)
|
2004-03-02 |
2013-06-19 |
ビルコ・ビーブイビーエイ |
臨床的カット−オフ値の推測
|
EP1598343A1
(fr)
*
|
2004-05-19 |
2005-11-23 |
Boehringer Ingelheim International GmbH |
Dérivés de 2-arylaminopyrimidines comme des inhibiteurs de PLK
|
EA010652B1
(ru)
|
2004-07-28 |
2008-10-30 |
Янссен Фармацевтика Н.В. |
Замещенные индолильные алкиламинопроизводные в качестве новых ингибиторов гистондеацетилазы
|
EP1797050B1
(fr)
|
2004-08-10 |
2013-10-23 |
Janssen Pharmaceutica NV |
Dérivés de 1,2,4-triazin-6-one destinés à inhiber le hiv
|
MX2007003796A
(es)
|
2004-09-30 |
2007-04-25 |
Tibotec Pharm Ltd |
Pirimidinas 5-sustituidas inhibidoras del virus de inmunodeficiencia humana.
|
US7531548B2
(en)
*
|
2004-09-30 |
2009-05-12 |
Tibotec Pharmaceuticals Ltd |
HIV inhibiting 5-carbo- or heterocyclic substituted pyrimidines
|
TW200626574A
(en)
|
2004-09-30 |
2006-08-01 |
Tibotec Pharm Ltd |
HIV inhibiting 5-heterocyclyl pyrimidines
|
CA2577588C
(fr)
|
2004-10-29 |
2013-09-10 |
Tibotec Pharmaceuticals Ltd. |
Derives de pyrimidine bicycliques inhibant le vih
|
EP1812069A2
(fr)
*
|
2004-11-08 |
2007-08-01 |
Boehringer Ingelheim International GmbH |
Methode de traitement d'infection vih par coadministration de tipranavir et etravirine
|
ATE540035T1
(de)
|
2004-11-24 |
2012-01-15 |
Rigel Pharmaceuticals Inc |
Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen
|
ES2337496T3
(es)
|
2005-01-19 |
2010-04-26 |
Rigel Pharmaceuticals, Inc. |
Profarmacos de compuestos de 2,4-pirimidindiamina y sus usos.
|
CN101107234B
(zh)
*
|
2005-01-27 |
2013-06-19 |
泰博特克药品有限公司 |
抑制hiv的2-(4-氰基苯氨基)嘧啶衍生物
|
PT1853588E
(pt)
|
2005-02-16 |
2008-08-25 |
Astrazeneca Ab |
Compostos químicos
|
MX2007010051A
(es)
*
|
2005-02-18 |
2007-09-21 |
Tibotec Pharm Ltd |
Derivados de oxido de 2-(4-cianofenilamino)pirimidina que inhiben el virus de inmunodeficiencia humana.
|
BRPI0609291B1
(pt)
*
|
2005-03-04 |
2022-02-08 |
Janssen Sciences Ireland Uc |
2-(4-ciano-fenil)-o-hidroxilamina-pirimidinas que inibem hiv, composição farmacêutica que as compreende e processo para a preparação de ambas
|
US20080287437A1
(en)
|
2005-05-16 |
2008-11-20 |
Astrazeneca Ab |
Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors
|
DK1888537T3
(da)
|
2005-05-26 |
2013-12-09 |
Janssen R & D Ireland |
Fremgangsmåde til fremstilling af 4[(1,6-dihydro-6-oxo-2-pyrimidinyl)amino]benzonitril
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
NZ563454A
(en)
|
2005-06-08 |
2011-03-31 |
Rigel Pharmaceuticals Inc |
2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway
|
EP1945208A4
(fr)
*
|
2005-10-06 |
2011-08-03 |
Univ Massachusetts |
Composition et synthese de nouveaux reactifs pour inhiber la replication du vih
|
PL1945631T3
(pl)
|
2005-10-28 |
2012-12-31 |
Astrazeneca Ab |
Pochodne 4-(3-aminopirazolo)pirymidyny do stosowania jako inhibitory kinazy tyrozynowej do leczenia raka
|
WO2007082874A1
(fr)
|
2006-01-19 |
2007-07-26 |
Janssen Pharmaceutica N.V. |
Dérivés de pyridine et de pyrimidine en tant qu'inhibiteurs d'histone désacétylase
|
SI1981874T1
(sl)
|
2006-01-19 |
2009-10-31 |
Janssen Pharmaceutica Nv |
Aminofenilni derivati kot novi inhibitorji histon deacetilaze
|
DK1981875T3
(da)
|
2006-01-19 |
2014-07-14 |
Janssen Pharmaceutica Nv |
Substituerede indolylalkylaminoderivater som inhibitorer af histondeacetylase
|
EP1991532B1
(fr)
|
2006-02-24 |
2017-01-11 |
Rigel Pharmaceuticals, Inc. |
Compositions et méthodes destinées à l'inhibition de la voie jak
|
EP2004632B1
(fr)
|
2006-03-30 |
2014-03-12 |
Janssen R&D Ireland |
Pyrimidines à substitution 5-amido inhibant le vih
|
DK2004641T3
(da)
|
2006-03-30 |
2011-01-24 |
Tibotec Pharm Ltd |
HIV-inhiberende 5-(hydroxymethylen og aminomethylen) substituerede pyrimidiner
|
US8623887B2
(en)
|
2006-05-15 |
2014-01-07 |
Boehringer Ingelheim International Gmbh |
Compounds
|
PT2029110E
(pt)
*
|
2006-06-06 |
2011-11-23 |
Tibotec Pharm Ltd |
Processo para preparar formulações secas por atomização de tmc125
|
EP2526932B1
(fr)
|
2006-06-19 |
2017-06-07 |
Alpharma Pharmaceuticals LLC |
Composition pharmaceutique
|
WO2008063301A2
(fr)
*
|
2006-10-11 |
2008-05-29 |
Alpharma, Inc. |
Compositions pharmaceutiques
|
WO2008068299A2
(fr)
|
2006-12-06 |
2008-06-12 |
Tibotec Pharmaceuticals Ltd. |
Sel de bromhydrate d'un composé anti-vih
|
JP5185283B2
(ja)
*
|
2006-12-29 |
2013-04-17 |
テイボテク・フアーマシユーチカルズ |
Hiv阻害6−置換ピリミジン
|
CN101573342A
(zh)
*
|
2006-12-29 |
2009-11-04 |
泰博特克药品有限公司 |
抑制hiv的5,6-取代的嘧啶类化合物
|
UA99459C2
(en)
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
US8410124B2
(en)
|
2007-10-18 |
2013-04-02 |
Concert Pharmaceuticals Inc. |
Deuterated etravirine
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
US20100151014A1
(en)
*
|
2008-12-16 |
2010-06-17 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
AU2008338442A1
(en)
*
|
2007-12-17 |
2009-06-25 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
SI2300013T1
(en)
|
2008-05-21 |
2018-03-30 |
Adriad Pharmacaceuticals, Inc. |
Phosphorus derivatives as kinase inhibitors
|
US9273077B2
(en)
|
2008-05-21 |
2016-03-01 |
Ariad Pharmaceuticals, Inc. |
Phosphorus derivatives as kinase inhibitors
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
US11351168B1
(en)
|
2008-06-27 |
2022-06-07 |
Celgene Car Llc |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
CA2986640C
(fr)
|
2008-06-27 |
2019-03-26 |
Celgene Avilomics Research, Inc. |
Composes hetero-aryles et leurs utilisations
|
TW201016676A
(en)
*
|
2008-10-03 |
2010-05-01 |
Astrazeneca Ab |
Heterocyclic derivatives and methods of use thereof
|
US20110071158A1
(en)
*
|
2009-03-18 |
2011-03-24 |
Boehringer Ingelheim International Gmbh |
New compounds
|
JP5748737B2
(ja)
|
2009-03-30 |
2015-07-15 |
ヤンセン・アールアンドデイ・アイルランド |
エトラビリンとニコチンアミドの共結晶
|
WO2010129053A2
(fr)
|
2009-05-05 |
2010-11-11 |
Dana Farber Cancer Institute |
Inhibiteurs d'egfr et procédés de traitement de troubles
|
WO2010131118A2
(fr)
*
|
2009-05-12 |
2010-11-18 |
Pliva Hrvatska D.O.O. |
Formes polymorphes d'étravirine et leurs procédés de préparation
|
WO2010150279A2
(fr)
|
2009-06-22 |
2010-12-29 |
Emcure Pharmaceuticals Limited |
Procédé pour la synthèse d'inhibiteur non nucléosidique de la transcriptase inverse diarylpyrimidine
|
US8153790B2
(en)
|
2009-07-27 |
2012-04-10 |
Krizmanic Irena |
Process for the preparation and purification of etravirine and intermediates thereof
|
GR1007010B
(el)
|
2009-10-08 |
2010-10-07 |
Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras), |
Ινσουλινοειδη πεπτιδια
|
CN103038230B
(zh)
|
2010-06-04 |
2016-05-25 |
霍夫曼-拉罗奇有限公司 |
作为lrrk2调节剂的氨基嘧啶衍生物
|
WO2012001695A1
(fr)
|
2010-06-28 |
2012-01-05 |
Hetero Research Foundation |
Procédé de préparation d'intermédiaire de l'étravirine et de polymorphes de l'étravirine
|
BR112013003388A2
(pt)
|
2010-08-10 |
2016-07-12 |
Celgene Avilomics Res Inc |
sal de besilato de um inibidor de btk
|
CA2812061A1
(fr)
|
2010-09-22 |
2012-03-29 |
Arena Pharmaceuticals, Inc. |
Modulateurs du recepteur gpr119 et traitement des troubles qui lui sont lies
|
US9238629B2
(en)
|
2010-11-01 |
2016-01-19 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
MX2013004894A
(es)
|
2010-11-01 |
2013-10-17 |
Celgene Avilomics Res Inc |
Compuestos heterociclicos y usos de los mismos.
|
JP5986094B2
(ja)
|
2010-11-10 |
2016-09-06 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Lrrk2調節薬としてのピラゾールアミノピリミジン誘導体
|
EP2637502B1
(fr)
|
2010-11-10 |
2018-01-10 |
Celgene CAR LLC |
Inhibiteurs d'egfr sélectifs d'un mutant et leurs utilisations
|
EP2702045B1
(fr)
|
2011-04-26 |
2017-10-18 |
Mylan Laboratories Ltd. |
Nouveau procédé de préparation d'étravirine
|
EP2704572B1
(fr)
|
2011-05-04 |
2015-12-30 |
Ariad Pharmaceuticals, Inc. |
Composés permettant d'inhiber la prolifération cellulaire dans les cancers induits par l'egfr
|
WO2012170647A1
(fr)
*
|
2011-06-09 |
2012-12-13 |
Assia Chemical Industriew Ltd. |
Procédé pour la préparation d'étravirine et intermédiaires dans la synthèse de celle-ci
|
CN103974955B
(zh)
|
2011-08-23 |
2018-06-19 |
阿萨纳生物科技有限责任公司 |
嘧啶并-哒嗪酮化合物及其用途
|
WO2013059572A1
(fr)
|
2011-10-19 |
2013-04-25 |
Assia Chemical Industries Ltd. |
Procédé de préparation d'etravarine et produits intermédiaires utiles dans la synthèse de ce composé
|
EP2770830A4
(fr)
|
2011-10-28 |
2015-05-27 |
Celgene Avilomics Res Inc |
Méthodes de traitement d'une maladie ou d'une affection associée à la tyrosine-kinase btk (bruton's tyrosine kinase)
|
US8703786B2
(en)
*
|
2011-12-07 |
2014-04-22 |
Texas Southern University |
Etravirine formulations and uses thereof
|
US9108927B2
(en)
|
2012-03-15 |
2015-08-18 |
Celgene Avilomics Research, Inc. |
Salts of an epidermal growth factor receptor kinase inhibitor
|
CA2866852C
(fr)
|
2012-03-15 |
2020-12-29 |
Celgene Avilomics Research, Inc. |
Formes solides d'un inhibiteur de kinases du recepteur du facteur de croissance epidermique
|
US20150166591A1
(en)
|
2012-05-05 |
2015-06-18 |
Ariad Pharmaceuticals, Inc. |
Methods and compositions for raf kinase mediated diseases
|
US20150336900A1
(en)
*
|
2012-10-29 |
2015-11-26 |
Biophore India Pharmaceuticals Pvt. Ltd. |
Process for the Synthesis of Etravirine and Its Intermediates
|
WO2014072419A1
(fr)
|
2012-11-08 |
2014-05-15 |
Universiteit Antwerpen |
Nouveaux composés anti-vih
|
WO2014100748A1
(fr)
|
2012-12-21 |
2014-06-26 |
Celgene Avilomics Research, Inc. |
Composés hétéroarylés et leurs utilisations
|
KR20150126595A
(ko)
|
2012-12-21 |
2015-11-12 |
벌릭스 파마 인코포레이티드 |
간 질환 또는 증상의 치료를 위한 용도 및 방법
|
MX2015009952A
(es)
|
2013-02-08 |
2015-10-05 |
Celgene Avilomics Res Inc |
Inhibidores de cinasas reguladas por señales extracelulares (erk) y sus usos.
|
US9611283B1
(en)
|
2013-04-10 |
2017-04-04 |
Ariad Pharmaceuticals, Inc. |
Methods for inhibiting cell proliferation in ALK-driven cancers
|
US9492471B2
(en)
|
2013-08-27 |
2016-11-15 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
|
US9415049B2
(en)
|
2013-12-20 |
2016-08-16 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
US10005760B2
(en)
|
2014-08-13 |
2018-06-26 |
Celgene Car Llc |
Forms and compositions of an ERK inhibitor
|
AU2016205361C1
(en)
|
2015-01-06 |
2021-04-08 |
Arena Pharmaceuticals, Inc. |
Methods of treating conditions related to the S1P1 receptor
|
CN104926829A
(zh)
*
|
2015-06-08 |
2015-09-23 |
山东大学 |
一种噻吩并嘧啶类衍生物及其制备方法和应用
|
KR102603199B1
(ko)
|
2015-06-22 |
2023-11-16 |
아레나 파마슈티칼스, 인크. |
S1p1 수용체-관련 장애에서의 사용을 위한 (r)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[b]인돌-3-일)아세트산 (화합물 1)의 결정성 l-아르기닌 염
|
CN110066273A
(zh)
*
|
2019-06-05 |
2019-07-30 |
山东大学 |
一种含三氮唑环的单芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法与应用
|
EP3994132A1
(fr)
|
2019-07-03 |
2022-05-11 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Inhibiteurs de tyrosine kinase non récepteur 1 (tnk1) et leurs utilisations
|
CN111217833B
(zh)
*
|
2020-02-21 |
2021-03-16 |
山东大学 |
噻吩并[2,3-d]嘧啶类HIV-1非核苷类逆转录酶抑制剂及其制备方法和应用
|
CN111875548A
(zh)
*
|
2020-07-16 |
2020-11-03 |
山东大学 |
一种5位芳环取代的二芳基嘧啶类衍生物及其制备方法与应用
|